Utilization of 31P-Nuclear Magnetic Resonance Spectroscopy to Monitor Brain Energy Deficit in Hun… (NCT01696708) | Clinical Trial Compass
CompletedNot Applicable
Utilization of 31P-Nuclear Magnetic Resonance Spectroscopy to Monitor Brain Energy Deficit in Huntington Disease
France50 participantsStarted 2012-12-06
Plain-language summary
The purpose of this project is to study brain energy profile evolution at different stages of the Huntington disease.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* UHDRS \< 50
* Age \> 18 years
* Ability to undergo MR scanning
* Covered by french social security
Exclusion Criteria:
* Evidence of psychiatric disorder
* Attendant neurological disorder
* Contraindications to MRI (claustrophobia, metallic or material implants)
* Severe head injury
* Unable to understand the protocol
* Pregnancy
* Failure to give informed consent
* Subjects with exclusion criteria required by french law (e.g. subjects who require a legally authorized representative to obtain consent)
* Unwillingness to be informed in case of abnormal MRI
What they're measuring
1
Ratio of Inorganic Phosphate (Pi) over phosphocreatine (PCr): Pi/PCr